摘要
目的分析阿奇霉素在肺炎支原体肺炎(MPP)患儿临床治疗中的效果。方法68例MPP患儿,随机分为参照组及实验组,每组34例。参照组采用红霉素治疗,实验组采用阿奇霉素治疗。比较两组患儿的临床疗效,血清炎症因子指标[γ-干扰素(IFN-γ)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平,不良反应发生情况。结果实验组临床总有效率94.12%高于参照组的73.53%,差异具有统计学意义(P<0.05)。治疗前,两组患儿的IFN-γ、IL-6、TNF-α水平比较,差异均无统计学意义(P>0.05);治疗7 d后,两组患儿的IFN-γ、IL-6、TNF-α水平均较本组治疗前降低,差异均具有统计学意义(t实验组=14.5692、18.0964、19.0762,P实验组=0.0000、0.0000、0.0000<0.05;t参照组=6.7283、8.5612、9.5989,P参照组=0.0000、0.0000、0.0000<0.05);且实验组患儿的IFN-γ、IL-6、TNF-α水平均低于参照组,差异具有统计学意义(P<0.05)。实验组患儿的不良反应发生率2.94%低于参照组的23.53%,差异具有统计学意义(P<0.05)。结论阿奇霉素可有效缓解MPP患儿的临床症状,减轻炎症反应,且不良反应较少,值得借鉴。
Objective To analyze the effect of azithromycin in the clinical treatment of children with Mycoplasma pneumoniae pneumonia(MPP). Methods A total of 68 MPP children were randomly divided into control group and experimental group, with 34 cases in each group. The control group was treated with erythromycin, and the experimental group was treated with azithromycin. The clinical efficacy, serum inflammatory factor indexes [γ-interferon(IFN-γ), interleukin-6(IL-6), tumor necrosis factor-α(TNF-α)] levels, and occurrence of adverse reactions were compared between the two groups. Results The total clinical effective rate 94.12% of the experimental group was higher than 73.53% of the control group, and the difference was statistically significan(P<0.05). Before treatment, there was no statistically significant difference in IFN-γ, IL-6 and TNF-α between the two groups(P>0.05). 7 d after treatment, IFN-γ, IL-6 and TNF-α of the two groups were lower than those before treatment, and the difference was statistically significant(texperimental group=14.5692, 18.0964, 19.0762, Pexperimental group=0.0000, 0.0000, 0.0000<0.05;tcontrol group=6.7283, 8.5612, 9.5989, Pcontrol group=0.0000, 0.0000, 0.0000<0.05). IFN-γ, IL-6 and TNF-α of the experimental group were lower than those of the control group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions 2.94% of the experimental group was lower than 23.53% of the control group, and the difference was statistically significant(P<0.05). Conclusion Azithromycin can effectively relieve the clinical symptoms of MPP children, reduce inflammatory reactions with less adverse reactions. It is worthy of reference.
作者
王文聪
杨福娣
王华萍
WANG Wen-cong;YANG Fu-di;WANG Hua-ping(Lianjiang People’s Hospital,Lianjiang 524400,China)
出处
《中国现代药物应用》
2020年第21期118-120,共3页
Chinese Journal of Modern Drug Application
关键词
阿奇霉素
儿科
肺炎支原体肺炎
不良反应
Azithromycin
Pediatrics
Mycoplasma pneumoniae pneumonia
Adverse reactions
